Literature DB >> 18596089

Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patient.

John K Odoom1, Zaira Yunus, Glynis Dunn, Philip D Minor, Javier Martín.   

Abstract

The evolution of the Sabin strain of type 1 poliovirus in a hypogammaglobulinemia patient for a period of 649 days is described. Twelve poliovirus isolates from sequential stool samples encompassing days 21 to 649 after vaccination with Sabin 1 were characterized in terms of their antigenic properties, virulence in transgenic mice, sensitivity for growth at high temperatures, and differences in nucleotide sequence from the Sabin 1 strain. Poliovirus isolates from the immunodeficient patient evolved gradually toward non-temperature-sensitive and neurovirulent phenotypes, accumulating mutations at key nucleotide positions that correlated with the observed reversion to biological properties typical of wild polioviruses. Analysis of plaque-purified viruses from stool samples revealed complex genetic and evolutionary relationships between the poliovirus strains. The generation of various coevolving genetic lineages incorporating different mutations was observed at early stages of virus excretion. The main driving force for genetic diversity appeared to be the selection of mutations at attenuation sites, particularly in the 5' noncoding region and the VP1 BC loop. Recombination between virus strains from the two main lineages was observed between days 63 and 88. Genetic heterogeneity among plaque-purified viruses at each time point seemed to decrease with time, and only viruses belonging to a unique genotypic lineage were seen from day 105 after vaccination. The relevance of vaccine-derived poliovirus strains for disease surveillance and future polio immunization policies is discussed in the context of the Global Polio Eradication Initiative.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18596089      PMCID: PMC2546908          DOI: 10.1128/JVI.00468-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  Circulating vaccine-derived polioviruses: current state of knowledge.

Authors:  Olen M Kew; Peter F Wright; Vadim I Agol; Francis Delpeyroux; Hiroyuki Shimizu; Neal Nathanson; Mark A Pallansch
Journal:  Bull World Health Organ       Date:  2004-02-26       Impact factor: 9.408

2.  Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion.

Authors:  J Martín; G Dunn; R Hull; V Patel; P D Minor
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  In vitro phenotypic markers of a poliovirus recombinant constructed from infectious cDNA clones of the neurovirulent Mahoney strain and the attenuated Sabin 1 strain.

Authors:  M Kohara; T Omata; A Kameda; B L Semler; H Itoh; E Wimmer; A Nomoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Trypsin sensitivity of the Sabin strain of type 1 poliovirus: cleavage sites in virions and related particles.

Authors:  C E Fricks; J P Icenogle; J M Hogle
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

5.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

6.  Hypogammaglobulinaemia in the United Kingdom. VII. The role of humoral antibodies in protection against and recovery from bacterial and virus infections in hypogammaglobulinaemia.

Authors:  F O MacCallum
Journal:  Spec Rep Ser Med Res Counc (G B)       Date:  1971

7.  Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia.

Authors:  Soile Blomqvist; Carita Savolainen; Pia Laine; Päivi Hirttiö; Elisa Lamminsalo; Eija Penttilä; Silver Jöks; Merja Roivainen; Tapani Hovi
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Vaccine policy changes and epidemiology of poliomyelitis in the United States.

Authors:  Lorraine Niño Alexander; Jane F Seward; Tammy A Santibanez; Mark A Pallansch; Olen M Kew; D Rebecca Prevots; Peter M Strebel; Joanne Cono; Melinda Wharton; Walter A Orenstein; Roland W Sutter
Journal:  JAMA       Date:  2004-10-13       Impact factor: 56.272

9.  Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man.

Authors:  Calman MacLennan; Glynis Dunn; Aarnoud P Huissoon; Dinakantha S Kumararatne; Javier Martin; Paula O'Leary; Ronald A Thompson; Husam Osman; Philip Wood; Philip Minor; David J Wood; Deenan Pillay
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

10.  Comparative biochemical studies of type 3 poliovirus.

Authors:  P D Minor
Journal:  J Virol       Date:  1980-04       Impact factor: 5.103

View more
  18 in total

1.  Genus-specific substitution rate variability among picornaviruses.

Authors:  Allison L Hicks; Siobain Duffy
Journal:  J Virol       Date:  2011-05-25       Impact factor: 5.103

2.  Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.

Authors:  Michael Famulare; Stewart Chang; Jane Iber; Kun Zhao; Johnson A Adeniji; David Bukbuk; Marycelin Baba; Matthew Behrend; Cara C Burns; M Steven Oberste
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

3.  Dynamics of Evolution of Poliovirus Neutralizing Antigenic Sites and Other Capsid Functional Domains during a Large and Prolonged Outbreak.

Authors:  Jing Shaw; Jaume Jorba; Kun Zhao; Jane Iber; Qi Chen; Festus Adu; Adekunle Adeniji; David Bukbuk; Marycelin Baba; Elizabeth Henderson; Naomi Dybdahl-Sissoko; Sharla McDonald; William C Weldon; Nicksy Gumede; M Steven Oberste; Olen M Kew; Cara C Burns
Journal:  J Virol       Date:  2018-04-13       Impact factor: 5.103

4.  The double-edged sword: How evolution can make or break a live-attenuated virus vaccine.

Authors:  Kathryn A Hanley
Journal:  Evolution (N Y)       Date:  2011-12

5.  A putative loop E motif and an H-H kissing loop interaction are conserved and functional features in a group C enterovirus RNA that inhibits ribonuclease L.

Authors:  Hannah L Townsend; Babal K Jha; Robert H Silverman; David J Barton
Journal:  RNA Biol       Date:  2008-10-09       Impact factor: 4.652

6.  Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria.

Authors:  Cara C Burns; Jing Shaw; Jaume Jorba; David Bukbuk; Festus Adu; Nicksy Gumede; Muhammed Ali Pate; Emmanuel Ade Abanida; Alex Gasasira; Jane Iber; Qi Chen; Annelet Vincent; Paul Chenoweth; Elizabeth Henderson; Kathleen Wannemuehler; Asif Naeem; Rifqiyah Nur Umami; Yorihiro Nishimura; Hiroyuki Shimizu; Marycelin Baba; Adekunle Adeniji; A J Williams; David R Kilpatrick; M Steven Oberste; Steven G Wassilak; Oyewale Tomori; Mark A Pallansch; Olen Kew
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

7.  Outbreak of type 2 vaccine-derived poliovirus in Nigeria: emergence and widespread circulation in an underimmunized population.

Authors:  Steven Wassilak; Muhammad Ali Pate; Kathleen Wannemuehler; Julie Jenks; Cara Burns; Paul Chenoweth; Emmanuel Ade Abanida; Festus Adu; Marycelin Baba; Alex Gasasira; Jane Iber; Pascal Mkanda; A J Williams; Jing Shaw; Mark Pallansch; Olen Kew
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

Review 8.  Mechanisms of viral emergence.

Authors:  Esteban Domingo
Journal:  Vet Res       Date:  2010-02-05       Impact factor: 3.683

9.  Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases.

Authors:  Minetaro Arita; Hua Ling; Dongmei Yan; Yorihiro Nishimura; Hiromu Yoshida; Takaji Wakita; Hiroyuki Shimizu
Journal:  BMC Infect Dis       Date:  2009-12-16       Impact factor: 3.090

10.  Evolution of type 2 vaccine derived poliovirus lineages. Evidence for codon-specific positive selection at three distinct locations on capsid wall.

Authors:  Tapani Hovi; Carita Savolainen-Kopra; Teemu Smura; Soile Blomqvist; Haider Al-Hello; Merja Roivainen
Journal:  PLoS One       Date:  2013-06-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.